FHL1 and acquired idiopathic inflammatory myopathy: Importantly, our study supports the hypothesis that anti-FHL1 autoantibodies are present in the early phase of the IIM disease, arguing against that anti-FHL1 autoantibodies are a consequence of muscle inflammation or muscle damage in patients with IIM.